000099777 001__ 99777
000099777 005__ 20230519145513.0
000099777 0247_ $$2doi$$a10.3390/toxins13020085
000099777 0248_ $$2sideral$$a123256
000099777 037__ $$aART-2021-123256
000099777 041__ $$aeng
000099777 100__ $$aEsteban, P.
000099777 245__ $$aIn Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus
000099777 260__ $$c2021
000099777 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099777 5203_ $$aMultidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) is one of the major causes of hospital-acquired and community infections and pose a challenge to the human health care system. Therefore, it is important to find new drugs that show activity against these bacteria, both in monotherapy and in combination with other antimicrobial drugs. Gliotoxin (GT) is a mycotoxin produced by Aspergillus fumigatus and other fungi of the Aspergillus genus. Some evidence suggests that GT shows antimicrobial activity against S. aureus in vitro, albeit its efficacy against multidrug-resistant strains such asMRSA or vancomycin-intermediate S. aureus (VISA) strainsis not known. This work aimedto evaluate the antibiotic efficacy of GT as monotherapy or in combination with other therapeutics against MRSA in vitro and in vivo using a Caenorhabditis elegans infection model.
000099777 536__ $$9info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R$$9info:eu-repo/grantAgreement/ES/MCIU-AEI/SAF2017-83120-C2-1-R
000099777 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099777 590__ $$a5.075$$b2021
000099777 592__ $$a0.884$$b2021
000099777 594__ $$a6.6$$b2021
000099777 591__ $$aTOXICOLOGY$$b20 / 94 = 0.213$$c2021$$dQ1$$eT1
000099777 593__ $$aToxicology$$c2021$$dQ1
000099777 591__ $$aFOOD SCIENCE & TECHNOLOGY$$b40 / 144 = 0.278$$c2021$$dQ2$$eT1
000099777 593__ $$aHealth, Toxicology and Mutagenesis$$c2021$$dQ1
000099777 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099777 700__ $$aRedrado, S.
000099777 700__ $$aComas, L.
000099777 700__ $$aDomingo, M.P.
000099777 700__ $$aMillán-Lou, M.I.
000099777 700__ $$0(orcid)0000-0002-9742-1463$$aSeral, C.$$uUniversidad de Zaragoza
000099777 700__ $$0(orcid)0000-0002-0036-6630$$aAlgarate, S.$$uUniversidad de Zaragoza
000099777 700__ $$aLopez, C.$$uUniversidad de Zaragoza
000099777 700__ $$0(orcid)0000-0001-7294-245X$$aRezusta, A.$$uUniversidad de Zaragoza
000099777 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J.$$uUniversidad de Zaragoza
000099777 700__ $$aArias, M.
000099777 700__ $$aGalvez, E.M.
000099777 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000099777 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000099777 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000099777 773__ $$g13, 2 (2021), 85 [16 pp]$$pToxins$$tToxins$$x2072-6651
000099777 8564_ $$s645822$$uhttps://zaguan.unizar.es/record/99777/files/texto_completo.pdf$$yVersión publicada
000099777 8564_ $$s2578058$$uhttps://zaguan.unizar.es/record/99777/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099777 909CO $$ooai:zaguan.unizar.es:99777$$particulos$$pdriver
000099777 951__ $$a2023-05-18-15:13:08
000099777 980__ $$aARTICLE